Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Anti-αIIb β3 immunization in Glanzmann thrombasthenia: review of literature and treatment recommendations.

Fiore M, d'Oiron R, Pillois X, Alessi MC.

Br J Haematol. 2018 Apr;181(2):173-182. doi: 10.1111/bjh.15087. Epub 2018 Apr 2. Review.

PMID:
29611179
2.

Perioperative management of a patient with Glanzmann thrombasthenia undergoing a coronary artery bypass graft surgery: a case report.

Kurdi M, Frère C, Amour J, Brumpt C, Delort J, Lebreton G, Croisille L, d'Oiron R, Martin-Toutain I.

Blood Coagul Fibrinolysis. 2018 Apr;29(3):327-329. doi: 10.1097/MBC.0000000000000719.

PMID:
29474205
3.

Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J; for FranceCoag Collaborators.

Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12.

4.

Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry.

Recht M, Rajpurkar M, Chitlur M, d'Oiron R, Zotz R, Di Minno G, Cooper DL, Poon MC.

Am J Hematol. 2017 Jul;92(7):646-652. doi: 10.1002/ajh.24741. Epub 2017 May 9.

PMID:
28370369
5.

The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany.

Berntorp E, Dargaud Y, Hart D, Lobet S, Mancuso ME, d'Oiron R, Perry D, Pollard D, van den Berg M, Blatný J, Chambost H, Doria AS, Holme PA, Kaczmarek R, Mantovani L, McLaughlin P, Nanayakkara L, Petrini P, Sannié T, Laane E, Maia R, Dettoraki A, Farrell A, Halimeh S, Raza S, Taylor S.

Eur J Haematol. 2017 Jan;98 Suppl 85:1-15. doi: 10.1111/ejh.12828.

PMID:
28101938
6.

Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).

Meunier S, d'oiron R, Chambost H, Dolimier E, Guillet B; ORTHem 15-25 Study Group.

Thromb Res. 2017 Mar;151:17-22. doi: 10.1016/j.thromres.2016.12.023. Epub 2016 Dec 28.

7.

Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015.

Astermark J, Hart D, Lobet S, Blatný J, d'Oiron R, Kenet G, Dolan G, Libotte V, Hermans C.

Eur J Haematol. 2016 Jul;97 Suppl 84:3-23. doi: 10.1111/ejh.12761.

PMID:
27292051
8.

The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.

Berntorp E, Hart D, Mancuso ME, d'Oiron R, Perry D, O'Mahony B, Kaczmarek R, Crato M, Pasi J, Miners A, Carlsson KS, Kitchen S, Boehlen F, Giangrande P, Cebura E, Uitslager N, Osooli M, Janeckova D, Haldon R, Rivolta GF.

Eur J Haematol. 2016 Jul;97 Suppl 83:3-18. doi: 10.1111/ejh.12760. Erratum in: Eur J Haematol. 2016 Dec;97(6):594.

PMID:
27272000
9.

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, Zawadzki C, Trossaert M, Itzhar-Baïkian N, Dreyfus M, d'Oiron R, Borel-Derlon A, Susen S, Bezieau S, Denis CV, Goudemand J; French Reference Center for von Willebrand disease.

Medicine (Baltimore). 2016 Mar;95(11):e3038. doi: 10.1097/MD.0000000000003038.

10.

New Insights Into the Treatment of Glanzmann Thrombasthenia.

Poon MC, Di Minno G, d'Oiron R, Zotz R.

Transfus Med Rev. 2016 Apr;30(2):92-9. doi: 10.1016/j.tmrv.2016.01.001. Epub 2016 Jan 30. Review.

11.

Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S, Scott DW, d'Oiron R, Lavigne-Lissalde G, Kenet G, Escuriola Ettingshausen C, Borel-Derlon A, Lambert T, Pasta G, Négrier C.

Haemophilia. 2016 Jan;22 Suppl 1:1-24. doi: 10.1111/hae.12860.

12.

[Mild hemophilia A fortuitously discovered during Henoch-Schönlein purpura].

Joly B, d'Oiron R, Desconclois C, Bendelac L, Rafowicz A, Meyzer C, Labrune P, Veyradier A.

Arch Pediatr. 2015 Nov;22(11):1167-70. doi: 10.1016/j.arcped.2015.07.014. Epub 2015 Sep 26. French.

PMID:
26412326
13.

The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.

Di Minno G, Zotz RB, d'Oiron R, Bindslev N, Di Minno MN, Poon MC; Glanzmann Thrombasthenia Registry Investigators.

Haematologica. 2015 Aug;100(8):1031-7. doi: 10.3324/haematol.2014.121475. Epub 2015 May 22.

14.

The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention.

Poon MC, d'Oiron R, Zotz RB, Bindslev N, Di Minno MN, Di Minno G; Glanzmann Thrombasthenia Registry Investigators.

Haematologica. 2015 Aug;100(8):1038-44. doi: 10.3324/haematol.2014.121384. Epub 2015 May 22.

15.

Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors.

Young G, Teitel J, d'Oiron R, Leissinger C, Berntorp E.

Clin Appl Thromb Hemost. 2015 Jan;21(1):10-8. doi: 10.1177/1076029614554993. Epub 2014 Oct 24.

PMID:
25343956
16.

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Calvez T, Chambost H, Claeyssens-Donadel S, d'Oiron R, Goulet V, Guillet B, Héritier V, Milien V, Rothschild C, Roussel-Robert V, Vinciguerra C, Goudemand J; FranceCoag Network.

Blood. 2014 Nov 27;124(23):3398-408. doi: 10.1182/blood-2014-07-586347. Epub 2014 Sep 24.

17.

Acquired haemophilia A associated with HIV infection: a rare disease.

Rivoisy C, D'Oiron R, Cherin M, Ségéral O, Meynard JL, Lambert T, Goujard C.

AIDS. 2014 Mar 27;28(6):931-2. doi: 10.1097/QAD.0000000000000172. No abstract available.

PMID:
24614066
18.

Characterization of four novel molecular changes in the promoter region of the factor VIII gene.

Nougier C, Roualdes O, Fretigny M, d'Oiron R, Costa C, Negrier C, Vinciguerra C.

Haemophilia. 2014 Mar;20(2):e149-56. doi: 10.1111/hae.12346. Epub 2013 Dec 30.

PMID:
24372689
19.

Cancer detection and management in patients with haemophilia: a retrospective European multicentre study.

Biron-Andreani C, de Moerloose P, D'oiron R, Chambost H, Schved JF, Hermans C.

Haemophilia. 2014 Jan;20(1):78-82. doi: 10.1111/hae.12250. Epub 2013 Aug 6.

PMID:
23919383
20.

Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.

Repessé Y, Peyron I, Dimitrov JD, Dasgupta S, Moshai EF, Costa C, Borel-Derlon A, Guillet B, D'Oiron R, Aouba A, Rothschild C, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S; ABIRISK consortium.

Haematologica. 2013 Oct;98(10):1650-5. doi: 10.3324/haematol.2013.084665. Epub 2013 May 28.

21.

Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.

Rothschild C, D'Oiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C.

Haemophilia. 2013 Mar;19(2):281-6. doi: 10.1111/hae.12018. Epub 2012 Oct 8.

PMID:
23038998
22.

How I treat inhibitors in haemophilia.

Makris M, Hay CR, Gringeri A, D'Oiron R.

Haemophilia. 2012 Jul;18 Suppl 4:48-53. doi: 10.1111/j.1365-2516.2012.02829.x.

PMID:
22726083
23.

Malignant disease in the haemophilic population: moving towards a management consensus?

Astermark J, Makris M, Mauser-Bunschoten E, Nemes L, D'oiron R, Oldenburg J, Ingerslev J; Malignancy in Haemophilia Workshop Group.

Haemophilia. 2012 Sep;18(5):664-71. doi: 10.1111/j.1365-2516.2012.02846.x. Epub 2012 May 28. Review.

PMID:
22630161
24.

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors.

Bonnet P, Gringeri A, Gomperts E, Leissinger CA, d'Oiron R, Teitel J, Young G, Franklin M, Ewenstein B, Berntorp E.

Am Health Drug Benefits. 2011 Jul;4(4):219-31.

25.

Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.

Pautard B, D'Oiron R, Li Thiao Te V, Lavend'homme R, Saint-Remy JM, Peerlinck K, Jacquemin M.

J Thromb Haemost. 2011 Jun;9(6):1163-70. doi: 10.1111/j.1538-7836.2011.04267.x.

26.

Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.

Berntorp E, Collins P, D'Oiron R, Ewing N, Gringeri A, Négrier C, Young G.

Haemophilia. 2011 Jan;17(1):e202-10. doi: 10.1111/j.1365-2516.2010.02377.x. Epub 2010 Sep 2.

PMID:
20825500
27.

Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.

d'Oiron R, Pipe SW, Jacquemin M.

Haemophilia. 2008 Jul;14 Suppl 3:138-46. doi: 10.1111/j.1365-2516.2008.01730.x. Review.

28.

Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.

Boekhorst J, Lari GR, D'Oiron R, Costa JM, Nováková IR, Ala FA, Lavergne JM, VAN Heerde WL.

Haemophilia. 2008 Jul;14(4):729-35. doi: 10.1111/j.1365-2516.2008.01694.x. Epub 2008 May 12.

PMID:
18503540
29.

Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.

Dasgupta S, Navarrete AM, André S, Wootla B, Delignat S, Repessé Y, Bayry J, Nicoletti A, Saenko EL, d'Oiron R, Jacquemin M, Saint-Remy JM, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2008 Jan;93(1):83-9. doi: 10.3324/haematol.11535.

30.

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

Teitel J, Berntorp E, Collins P, D'Oiron R, Ewenstein B, Gomperts E, Goudemand J, Gringeri A, Key N, Leissinger C, Monahan P, Young G.

Haemophilia. 2007 May;13(3):256-63.

PMID:
17498074
31.

Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution.

Guillet B, Lambert T, d'Oiron R, Proulle V, Plantier JL, Rafowicz A, Peynet J, Costa JM, Bendelac L, Laurian Y, Lavergne JM.

Hum Mutat. 2006 Jul;27(7):676-85.

PMID:
16786531
32.

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

d'Oiron R, Volot F, Reynaud J, Peerlinck K, Goudemand J, Guérois C, Rothschild C, Chambost H, Borel-Derlon A, Roussel-Robert V, Marquès-Verdier A, Lienhart A, Berthier AM, Moreau P, Lambert T; MHAI Study Group.

Semin Hematol. 2006 Jan;43(1 Suppl 1):S3-9.

PMID:
16427382
33.

Factor XI deficiency: identification of six novel missense mutations (P23L, P69T, C92G, E243D, W497C and E547K).

Quélin F, François D, d'Oiron R, Guillet B, de Raucourt E, de Mazancourt P.

Haematologica. 2005 Aug;90(8):1149-50.

34.

First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene.

Hilbert L, D'Oiron R, Fressinaud E, Meyer D, Mazurier C; INSERM Network on Molecular Abnormalities in von Willebrand Disease.

J Thromb Haemost. 2004 Dec;2(12):2271-3. No abstract available.

35.

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.

Poon MC, D'Oiron R, Von Depka M, Khair K, Négrier C, Karafoulidou A, Huth-Kuehne A, Morfini M; International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group.

J Thromb Haemost. 2004 Jul;2(7):1096-103.

36.

Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?

Giansily-Blaizot M, Verdier R, Biron-Adréani C, Schved JF, Bertrand MA, Borg JY, Le Cam-Duchez V, Briquel ME, Chambost H, Pouymayou K, Dutrillaux F, Favier R, Martin-Toutain I, Verdy E, Gay V, Goudemand J, Navarro R, Durin A, d'Oiron R, Lambert T, Pernod G, Barrot C, Peynet J, Bastenaire B, Sie P, Stieltjes N, Torchet MF, de Moerloose P; Study group of FVII deficiency.

Haematologica. 2004 Jun;89(6):704-9. Erratum in: Haematologica. 2007 Nov;92(11):1584. LeCam-Duchez, V [corrected to Le Cam-Duchez, V].

37.

Reappraisal of in utero stem cell transplantation based on long-term results.

Touraine JL, Raudrant D, Golfier F, Rebaud A, Sembeil R, Roncarolo MG, Bacchetta R, D'Oiron R, Lambert T, Gebuhrer L.

Fetal Diagn Ther. 2004 Jul-Aug;19(4):305-12. Review.

PMID:
15192288
38.

Restricted BV gene usage by factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A.

Misra N, Bayry J, Pashov A, Kaveri SV, D'Oiron R, Stieltjes N, Roussel-Robert V, Kazatchkine MD, Boyer O, Lacroix-Desmazes S.

Thromb Haemost. 2003 Nov;90(5):813-22.

PMID:
14597975
39.

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.

d'Oiron R, Lavergne JM, Lavend'homme R, Benhida A, Bordet JC, Negrier C, Peerlinck K, Vermylen J, Saint-Remy JM, Jacquemin M.

Blood. 2004 Jan 1;103(1):155-7. Epub 2003 Sep 11.

40.

Molecular mechanisms of mild and moderate hemophilia A.

Jacquemin M, De Maeyer M, D'Oiron R, Lavend'Homme R, Peerlinck K, Saint-Remy JM.

J Thromb Haemost. 2003 Mar;1(3):456-63. Review. Erratum in: J Thromb Haemost. 2003 Dec;1(12):2722.

41.

Two novel cases of cerebral haemorrhages at the neonatal period associated with inherited factor VII deficiency, one of them revealing a new nonsense mutation (Ser52Stop).

Giansily-Blaizot M, Aguilar-Martinez P, Briquel ME, d'Oiron R, De Maistre E, Epelbaum S, Schved JF.

Blood Coagul Fibrinolysis. 2003 Feb;14(2):217-20. Review.

PMID:
12632035
42.

Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies.

Martin I, Kriaa F, Proulle V, Guillet B, Kaplan C, D'Oiron R, Debré M, Fressinaud E, Laurian Y, Tchernia G, Charpentier B, Lambert T, Dreyfus M.

Br J Haematol. 2002 Dec;119(4):991-7.

PMID:
12472579
43.

The prevalence of proteolytic antibodies against factor VIII in hemophilia A.

Lacroix-Desmazes S, Bayry J, Misra N, Horn MP, Villard S, Pashov A, Stieltjes N, d'Oiron R, Saint-Remy JM, Hoebeke J, Kazatchkine MD, Reinbolt J, Mohanty D, Kaveri SV.

N Engl J Med. 2002 Feb 28;346(9):662-7.

44.

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

Poon MC, d'Oiron R, Hann I, Négrier C, de Lumley L, Thomas A, Karafoulidou A, Demers C, Street A, Huth-Kühne A, Petrini P, Fressinaud E, Morfini M, Tengborn L, Marquès-Verdier A, Musso R, Devecioglu O, Houston DS, Lethagen S, Van Geet C, von Depka M, Berger C, Beurrier P, Britton HA, Gerrits W, Guthner C, Kuhle S, Lorenzo JJ, Makris PE, Nohe N, Paugy P, Pautard B, Torchet MF, Trillot N, Vicariot M, Wilde J, Winter M, Chambost H, Ingerslev J, Peters M, Strauss G.

Semin Hematol. 2001 Oct;38(4 Suppl 12):21-5. Review.

PMID:
11735106
45.

Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia.

Guillet B, Kriaa F, Huysse MG, Proulle V, George C, Tchernia G, D'Oiron R, Laurian Y, Charpentier B, Lambert T, Dreyfus M.

Br J Haematol. 2001 Sep;114(4):837-44.

PMID:
11564072
46.

Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.

Christophe OD, Lenting PJ, Cherel G, Boon-Spijker M, Lavergne JM, Boertjes R, Briquel ME, de Goede-Bolder A, Goudemand J, Gaillard S, d'Oiron R, Meyer D, Mertens K.

Blood. 2001 Sep 1;98(5):1416-23.

47.

Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes.

Neerman-Arbez M, de Moerloose P, Honsberger A, Parlier G, Arnuti B, Biron C, Borg JY, Eber S, Meili E, Peter-Salonen K, Ripoll L, Vervel C, d'Oiron R, Staeger P, Antonarakis SE, Morris MA.

Hum Genet. 2001 Mar;108(3):237-40.

PMID:
11354637
48.

[Which urologic treatment alternatives are there for the hemophiliac patient?].

Benoit G, Lambert T, Blanchet P, Laurian Y, Lasjaunias P, D'Oiron R, Eschwege P, Langloys J, Droupy S, Kriaa F, Jardin A.

Prog Urol. 2000 Jun;10(3):388-96. French.

PMID:
10951931
49.

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.

Jacquemin M, Lavend'homme R, Benhida A, Vanzieleghem B, d'Oiron R, Lavergne JM, Brackmann HH, Schwaab R, VandenDriessche T, Chuah MK, Hoylaerts M, Gilles JG, Peerlinck K, Vermylen J, Saint-Remy JM.

Blood. 2000 Aug 1;96(3):958-65.

50.

Mutations in the fibrinogen aalpha gene account for the majority of cases of congenital afibrinogenemia.

Neerman-Arbez M, de Moerloose P, Bridel C, Honsberger A, Schönbörner A, Rossier C, Peerlinck K, Claeyssens S, Di Michele D, d'Oiron R, Dreyfus M, Laubriat-Bianchin M, Dieval J, Antonarakis SE, Morris MA.

Blood. 2000 Jul 1;96(1):149-52.

Supplemental Content

Loading ...
Support Center